Immune checkpoint inhibitors (ICI) are an integral part of bladder cancer therapy, however, the relevance of ICI treatment for mixed and pure squamous cell carcinoma of the bladder remains poorly studied. | Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation